The Dexcom G4 PLATINUM system consists of three parts: a sensor, transmitter and monitor. According to the company, features include a long transmission range, small profile, LCD display, customizable alerts with specific tones and a “hypo alert” setting at 55 mg/dl.
“Improved accuracy in the critical hypoglycemic range is most important from a life-saving point of view,” said Terrance H. Gregg, Dexcom CEO, in the release. “The Dexcom G4 PLATINUM fulfills the promise of CGM for people with diabetes by providing accurate and reliable real-time performance.”
Dexcom is headquartered in San Diego.
Related Articles on FDA Clearances:
FDA Approves Stivarga for Metastatic Colorectal Cancer
Covidien Receives FDA Clearance for Bedside Respiratory Patient Monitoring System
Boston Scientific Receives FDA Clearance for Subcutaneous Implantable Defibrillator
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.